Predictive Clinical and Pathological Factors for Treatment Response in Locally Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
Eastern Journal of Medicine, cilt.31, sa.3, ss.491-500, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.5505/ejm.2026.01033
- Dergi Adı: Eastern Journal of Medicine
- Derginin Tarandığı İndeksler: Scopus, EMBASE, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Sayfa Sayıları: ss.491-500
- Anahtar Kelimeler: Gastric adenocarcinoma, neoadjuvant chemotherapy, pathological response, prognostic factors, treatment response
- Van Yüzüncü Yıl Üniversitesi Adresli: Evet
Özet
Predictive Clinical and Pathological Factors for Treatment Response in Locally Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy This study aimed to identify the clinical and pathological determinants associated with treatment response among patients diagnosed with locally advanced gastric cancer who underwent neoadjuvant chemotherapy. Retrospective data of 106 patients with locally advanced gastric carcinoma who presented to the Medical Oncology Outpatient Clinic of Van Yuzuncu Yil University Faculty of Medicine between 2010 and 2023 were analyzed. Patients who received neoadjuvant chemotherapy and subsequently underwent surgery were included. Demographic data, laboratory findings, histopathological characteristics, and treatment response were evaluated. In the group that demonstrated pathological response, clinical T stage, vascular/perineural invasion, ECOG score, TNM stage, number of metastatic lymph nodes, and CAP-TRG score were significantly lower (p < 0.05). This group also had higher rates of curative surgery, intestinal-type Lauren classification, moderate/well differentiation, CA19-9 and PDW values, and lower rates of neuropathy and stomatitis. Patients who achieved a pathological response demonstrated markedly improved overall and disease-free survival outcomes (p < 0.05). High T stage, poorly differentiated histology, high ECOG score, and low CA19-9 levels were associated with lack of treatment response. A significant survival advantage was observed in patients who responded to neoadjuvant therapy.